ArticleFrontiers in cellular and infection microbiology2025
The impact of diabetes mellitus on biomarkers for the diagnosis of periprosthetic joint infection.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Passive, Electromagnetic-Responsive Hydrogel Immunosensor for Exercise Intensity Monitoring Based on Sweat C-Reactive Protein.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study is to explore the impact of diabetes on the diagnosis of periprosthetic joint infection (PJI) by evaluating the levels of biomarkers and their diagnostic efficacy. Methods: According to the diagnostic criteria for diabetes mellitus (DM), 394 patients were divided into the DM group (n=113) and the Non-DM group (n=281); each of these two groups was further subdivided into the PJI group and the aseptic loosening (AL) group based on the presence or absence of PJI. The levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen (FIB), D-dimer, CRP-albumin ratio (CAR), and CRP-FIB ratio (CFR) were collected from all patients. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic efficacy of the aforementioned biomarkers under different glucose metabolism statuses. Results: In both the DM group and the Non-DM group, the levels of all biomarkers in patients with PJI were significantly higher than those in patients with AL (P<0.001). The CAR showed the highest diagnostic efficacy in both groups (AUC = 0.918 in the DM group and AUC = 0.931 in the Non-DM group). Notably, compared with the Non-DM group, the optimal cut-off values of CRP and ESR were elevated in the DM group (CRP: 9.960 mg/L vs 7.895 mg/L; ESR: 43.0 mm/h vs 36.5 mm/h). Conclusion: Diabetes does not affect the biomarker levels in patients with PJI. However, for diabetic patients, the diagnostic thresholds of CRP and ESR are relatively higher. Thus, caution should be exercised in clinical diagnosis to avoid false positives. Among all indicators, the CAR demonstrates the best diagnostic efficacy and can serve as the preferred biomarker for PJI patients with comorbid diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.